Replies to post #239131 on Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

I really don't know. Too many variables here. Especially, since we don't have Prurisol ph2b psoriasis trial results yet. Plus, we don't know whether or not Brilacidin ph2 OM received BTD.

You are probably correct that we'd get more in the long run with a partnership than with a buyout. The royalties will pay out more since these drugs are in large markets.






In Reply to 'FarmaZutical'
Hi Karin, I’m curious as to what you’d think a fair buyout price would be ? Normally, you’d not see a premium exceed 100 % maximum, and at the current levels that would still leave many long time holders severely in red. I’m hoping for a partnership.

[frrol]

Buyout prices for pre-rev biotechs are based primarily on projected revenue multiples. A distant secondary consideration is previous stock price, and with a huge caveat: It is not the current stock price that matters but the "recent high". And if that high implies a buyout price that is financially unjustifiable, it is ignored. And keep in mind we have issued a lot of shares since our highs, which would make it even less justifiable.
That being said, our diluted market cap high was around $700MM, and that is high but not an outlandish price and would now come to over $3 per share. If P results are good, that could be doubled. If incredible, tripled. (Ignore the dumb pumping.)